Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of acromegaly~* Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months~* Biochemical control (IGF -1 \< 1.3 x ULN and GH \< 2.5ng/mL)~Exclusion Criteria:~* Injections of long-acting somatostatin analogs, at a dosing interval \> 8 weeks.~* Pituitary radiotherapy within 5 years~* Pituitary surgery within six months~* Patients who previously participated in CH-ACM-01 study~* Any clinically significant uncontrolled concomitant disease~* Symptomatic cholelithiasis~* Previous treatment with:~* Pegvisomant, within 12 weeks~* Dopamine agonists, within 6 weeks~* Pasireotide, within 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Run-in phase (Type: EXPERIMENTAL): Oral octreotide capsules
- RCT phase - Oral (Type: EXPERIMENTAL): Oral octreotide capsules
- RCT phase - Injectables (Type: ACTIVE_COMPARATOR): Injectable somatostatin analogs (octreotide or lanreotide)
- Combination phase (sub-study) (Type: EXPERIMENTAL): Octreotide capsules plus cabergoline

Based on this trial design, predict the completion outcome and termination type (if applicable).